Participant flow

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma · Source last updated 2017-08-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   IMC-A12 + Multi-agent intensive chemotherapy regimen.

   id

   FG000

   title

   IMC-A12

2. description

   Add temozolomide to vincristine/irinotecan cycles.

   id

   FG001

   title

   Temozolomide

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         7

      2. group Id

         FG001

         num Subjects

         4

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         1

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         19

      type

      Lack of Efficacy

   4. reasons

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         5

      type

      Physician Decision

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Withdrawal by Subject

   6. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         5

      type

      Ineligible

   7. reasons

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         4

      type

      Refusal of further protocol therapy

   8. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      No treatment

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         100

      2. group Id

         FG001

         num Subjects

         75

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         55

      2. group Id

         FG001

         num Subjects

         37

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         45

      2. group Id

         FG001

         num Subjects

         38

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The number of participants started is 175. Eight patients were declared ineligible by the study chair, and one patient didn't receive treatment.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice